Back

Limited impact of concomitant coronary artery by-pass grafting on long-term outcomes after surgical aortic valve replacement: a nationwide propensity matched study

31 August 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Factors affecting prognosis of CABG patients Coronary Arteries ESC Premium Access ESC Congress 2019

About the speaker

Photo
Doctor Ville Kyto

Turku University Hospital, Turku (Finland)

4 More presentations in this session

Presentation thumbnail
Effect of ticagrelor plus aspirin, ticagrelor alone, or aspirin alone on vein-graft patency 1 year after coronary artery bypass grafting with or without diabetes: a post-hoc analysis of the DACAB tria
Doctor Y. Zhu (Shanghai, CN)
Abstract Slides Video
Presentation thumbnail
Preoperative dual antiplatelet therapy and early outcomes in patients undergoing coronary artery bypass grafting
Doctor J. Qu (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
"New-onset atrial fibrillation efter cardiac surgery is associated with increased long-term morbidity and mortality": a population-based study from the SWEDEHEART-registry.
Doctor A. Taha (Gothenburg, SE)
Abstract Slides Video
Presentation thumbnail
The randomised study of epicardial application of hydrogel with amiodarone for prevention of postoperative atrial fibrillation in patients after coronary artery bypass grafting
Doctor T. Kanametov (Moscow, RU)
Abstract Slides Video

Access the full session

Session thumbnail
Factors affecting prognosis of CABG patients

The Event

Event poster

ESC Congress 2019

31 August - 4 September 2019
You may be interested in
thumbnail
Congress Presentation
Anomalous left main coronary artery arising from the right coronary sinus presenting with ST elevation and non ST elevation myocardial infarction
thumbnail
Congress Presentation
Surgical correction of anomalous origin of the coronary artery: a scoping review on clinical outcomes, techniques, and knowledge gaps
thumbnail
Webinar
Chronic coronary syndrome post-myocardial infarction: disease progression and comorbidities

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources